Innocenti Receives R21 Grant to Personalize Angiogenesis Inhibitors to Individual Cancer Patients
August 20, 2014
Federico Innocenti receives a $275,000 NCI grant to study the role a cancer patient’s genetic makeup plays in the effectiveness of angiogenesis inhibitors. Angiogenesis inhibitors stop or slow the spread of tumors by choking off the blood supply that feeds … Read more